Emergent BioSolutions, Inc. (EBS)
6.23
0.00 (0.00%)
USD |
NYSE |
Oct 23, 16:00
6.24
+0.01
(+0.16%)
After-Hours: 20:00
Emergent BioSolutions Enterprise Value : 766.90M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 766.90M |
| October 22, 2026 | 766.90M |
| October 21, 2026 | 765.36M |
| October 20, 2026 | 769.98M |
| October 19, 2026 | 773.57M |
| October 16, 2026 | 774.59M |
| October 15, 2026 | 815.63M |
| October 14, 2026 | 801.78M |
| October 13, 2026 | 801.78M |
| October 12, 2026 | 805.37M |
| October 09, 2026 | 809.48M |
| October 08, 2026 | 796.65M |
| October 07, 2026 | 809.99M |
| October 06, 2026 | 803.84M |
| October 05, 2026 | 818.71M |
| October 02, 2026 | 772.03M |
| October 01, 2026 | 774.08M |
| September 30, 2026 | 785.88M |
| September 29, 2026 | 802.30M |
| September 28, 2026 | 799.22M |
| September 25, 2026 | 795.63M |
| September 24, 2026 | 794.60M |
| September 23, 2026 | 789.47M |
| September 22, 2026 | 794.09M |
| September 21, 2026 | 783.32M |
| Date | Value |
|---|---|
| September 18, 2026 | 796.14M |
| September 17, 2026 | 807.43M |
| September 16, 2026 | 793.58M |
| September 15, 2026 | 773.57M |
| September 14, 2026 | 774.59M |
| September 11, 2026 | 766.90M |
| September 10, 2026 | 748.43M |
| September 09, 2026 | 738.68M |
| September 08, 2026 | 755.10M |
| September 04, 2026 | 765.87M |
| September 03, 2026 | 766.90M |
| September 02, 2026 | 778.70M |
| September 01, 2026 | 766.39M |
| August 31, 2026 | 760.23M |
| August 28, 2026 | 750.48M |
| August 27, 2026 | 752.02M |
| August 26, 2026 | 753.56M |
| August 25, 2026 | 736.63M |
| August 24, 2026 | 713.03M |
| August 21, 2026 | 707.90M |
| August 20, 2026 | 694.57M |
| August 19, 2026 | 698.16M |
| August 18, 2026 | 686.36M |
| August 17, 2026 | 678.15M |
| August 14, 2026 | 682.77M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Exelixis, Inc. | 15.39B |
| Arcturus Therapeutics Holdings, Inc. | 111.13M |
| Capricor Therapeutics, Inc. | 197.70M |
| ADMA Biologics, Inc. | 2.475B |
| Akebia Therapeutics, Inc. | 207.61M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -180.20M |
| Revenue (Quarterly) | 234.30M |
| Total Expenses (Quarterly) | 414.50M |
| EPS Diluted (Quarterly) | -3.492 |
| Gross Profit Margin (Quarterly) | 51.22% |
| Profit Margin (Quarterly) | -76.91% |
| Earnings Yield | -57.04% |
| Operating Earnings Yield | 40.51% |
| Normalized Earnings Yield | -7.368 |